Last reviewed · How we verify
Boceprevir, Peg-interferon alfa 2b and Ribavirin
Boceprevir, Peg-interferon alfa 2b and Ribavirin is a Small molecule drug developed by ANRS, Emerging Infectious Diseases. It is currently in Phase 2 development. Also known as: ViraferonPeg, Rebetol.
At a glance
| Generic name | Boceprevir, Peg-interferon alfa 2b and Ribavirin |
|---|---|
| Also known as | ViraferonPeg, Rebetol |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Anaemia
- Pyrexia
- Fatigue
- Alopecia
- Myalgia
- Headache
- Nausea
- Dizziness
- Insomnia
- Decreased appetite
- Neutropenia
- Dysgeusia
Key clinical trials
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) (PHASE2)
- Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection (PHASE3)
- Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) (PHASE2, PHASE3)
- Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107) (PHASE3)
- Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED) (PHASE3)
- An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
- Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED) (PHASE2)
- Boceprevir in End Stage Renal Disease (ESRD) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Boceprevir, Peg-interferon alfa 2b and Ribavirin CI brief — competitive landscape report
- Boceprevir, Peg-interferon alfa 2b and Ribavirin updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI
Frequently asked questions about Boceprevir, Peg-interferon alfa 2b and Ribavirin
What is Boceprevir, Peg-interferon alfa 2b and Ribavirin?
Boceprevir, Peg-interferon alfa 2b and Ribavirin is a Small molecule drug developed by ANRS, Emerging Infectious Diseases.
Who makes Boceprevir, Peg-interferon alfa 2b and Ribavirin?
Boceprevir, Peg-interferon alfa 2b and Ribavirin is developed by ANRS, Emerging Infectious Diseases (see full ANRS, Emerging Infectious Diseases pipeline at /company/anrs-emerging-infectious-diseases).
Is Boceprevir, Peg-interferon alfa 2b and Ribavirin also known as anything else?
Boceprevir, Peg-interferon alfa 2b and Ribavirin is also known as ViraferonPeg, Rebetol.
What development phase is Boceprevir, Peg-interferon alfa 2b and Ribavirin in?
Boceprevir, Peg-interferon alfa 2b and Ribavirin is in Phase 2.
What are the side effects of Boceprevir, Peg-interferon alfa 2b and Ribavirin?
Common side effects of Boceprevir, Peg-interferon alfa 2b and Ribavirin include Anaemia, Pyrexia, Fatigue, Alopecia, Myalgia, Headache.
Related
- Manufacturer: ANRS, Emerging Infectious Diseases — full pipeline
- Also known as: ViraferonPeg, Rebetol
- Compare: Boceprevir, Peg-interferon alfa 2b and Ribavirin vs similar drugs
- Pricing: Boceprevir, Peg-interferon alfa 2b and Ribavirin cost, discount & access